ResMed restructures exec team 

SAN DIEGO – ResMed has implemented a new operating model that adds dedicated leadership in product, revenue and marketing to its global executive team. 

“ResMed is the undisputed leader in digital health for respiratory medicine and residential care, and we aspire to make ourselves even more product-led customer-centric, and brand-enhanced,” said Mick Farrell, ResMed’s CEO. “Today, we are making bold changes to ensure these capabilities are directly represented in our executive leadership team. We will measure the success of our new operating model through increased product velocity, increased vigilance on long-term profitable revenue delivery and increased brand engagement with stakeholders.” 

Leaders appointed into new roles: 

• Chief Product Officer – Justin Leong (previously president, Asia and Latin America) 

• Chief Marketing Officer – Katrin Pucknat (previously president, Germany) 

• Chief Revenue Officer – Mike Fliss (previously vice president, North America sales) 

In addition to the above roles, the executive leadership team also includes: 

• Chief Commercial Officer, SaaS – Bobby Ghoshal 

• Chief Financial Officer – Brett Sandercock 

• Chief Legal Officer – Mike Rider 

• Chief People Officer – Vered Keisar 

• Chief Strategy Officer – Hemanth Reddy 

The extended CEO operations team, reporting directly to the CEO, includes: 

• Chief Compliance Officer – Jim Ellis 

• Chief Information Security Officer – Todd Friedman 

• Chief Investor Relations Officer – Amy Wakeham 

• Chief Medical Officer – Carlos Nunez 

• Chief Quality & Regulatory Officer – Dawn Haake 

• Chief Supply Chain Officer – Andrew Price 

Resmed also announced that Rob Douglas, current president and COO, plans to retire on Jan. 1. He will immediately transition to a new role as special adviser to the CEO and will remain in a consulting role through Dec. 31, 2024. 

Additionally, Lucile Blaise, president of sleep and respiratory care, will immediately transition to a new role as senior vice president, strategy & business development, reporting to Reddy. Finally, Leong will oversee the digital health technology product organization, and Urvashi Tyagi, chief technology officer, will transition to a role as special advisor to the chief product officer through Jan. 1, 2024, and will remain in a consulting role through Dec. 31, 2024.